RECENT NEWS

Proscia will add AI biomarker detection for skin tissue to its Concentriq software platform. Powered by Primaa, Cleo Skin will strengthen Concentriq’s lead in offering the industry’s broadest portfolio of AI solutions on a single platform.

Artificial intelligence (AI) tools that could transform patient care – from reducing bowel cancer test times from weeks to minutes, to detecting skin cancer and genetic eye diseases sooner – are being tested in the next phase of the Medicines and Healthcare products Regulatory Agency’s (MHRA) AI Airlock programme.

The National Institute for Health and Care Research (NIHR) has added a new Translational Research Collaboration in Infection and Antimicrobial Resistance (AMR) to its portfolio.

Leading Alzheimer's disease experts at this year's Alzheimer Europe Conference, in partnership with Eli Lilly and Company, have called for urgent improvements to diagnostic pathways to ensure people in Europe can benefit from new therapeutic innovation.

A study carried out by a team of researchers from The Institute of Cancer Research has identified a more accurate way of predicting which multiple myeloma patients are likely to relapse early following treatment.

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Hologic’s Panther Fusion Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. The assays also now have CE marking in the European Union in accordance with the In Vitro Diagnostic Regulation (IVDR).

Precision proteomics firm Alamar Biosciences has announced the launch of the NULISAqpcr BD-pTau217 Assay, which it says is a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217 (pTau217)—a pivotal biomarker in Alzheimer's disease research and other tauopathies.

Bio-Techne Corporation has announced a significant enhancement to its agreement with Oxford Nanopore Technologies, broadening Bio-Techne's ability to develop a portfolio of genetic products on Oxford Nanopore Technologies platforms and extending the collaboration.

SARSTEDT was the winner of the Best Stand Award at the IBMS Congress 2025, held at ICC Birmingham. Sponsored by Pro-Lab Diagnostics and BIVDA, the award recognises excellence in exhibition design, visitor engagement, and innovation in biomedical sciences.

Dr Riina Richardson, one of the UK’s leading experts in fungal infections, has been elected the next President of the British Society for Medical Mycology (BSMM) – one of the oldest specialist societies for human and animal fungal disease in the world.

A new independent report by the International Pandemic Preparedness Secretariat (IPPS), the Brown University Pandemic Center and FIND, the global alliance for diagnostics, has identified persistent barriers in diagnostic preparedness that continue to undermine efforts to prevent future pandemics.

The new Moderna Innovation and Technology Centre, which will develop and manufacture mRNA vaccines, has been officially opened by Health and Social Care Secretary Wes Streeting.

Alpenglow Biosciences, a leader in AI-powered 3D pathology, has announced a strategic agreement with Virdx, a biophysics AI company focused on MRI-based cancer detection, with the two firms collaborating to accelerate the development of tools that bridge radiology and pathology.

The International Association for the Study of Lung Cancer (IASLC) Pathology Committee has proposed a simple, prognostically relevant grading system for resected invasive LUSC based on tumour budding, in a newly published study.

Pathways to Antimicrobial Clinical Efficacy (PACE) has recently launched its third funding round, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health.

Ataraxis AI, a frontier laboratory developing artificial intelligence–powered prognostic tools for oncology, and Medica Scientia Innovation Research (MEDSIR), a global leader in oncology research, have announced a strategic collaboration to integrate AI into multiple major international trials.

The time it takes to approve clinical trials in the UK has been cut by more than half – from an average of 91 days to just 41 days – following major reforms backed by new digital platforms at the Medicines and Healthcare products Regulatory Agency (MHRA), new research has confirmed.

Breath biopsy firm Owlstone Medical has announced that it has won an award of up to $49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop its POSEIDON programme to enable accurate, low-cost, accessible cancer screening.

The UK Sepsis Trust has commissioned and is fully funding a new study, led by the University of St Andrews, which aims to improve sepsis diagnosis and lead to lifesaving interventions.

Swedish firm Inify Laboratories, which offers prostate cancer diagnostics, has chosen Milton Park in Oxfordshire as the site for its first UK laboratory.